Bluefront acquires 80% stake in Cryogenetics
2024-10-21T14:11:00
Bluefront Equity has announced its biggest ever investment with the majority acquisition of aquaculture technology specialist, Cryogenetics
Through its Capital II fund Bluefront will own around 80% of shares with the remainder split between co-owner, Investinor, and Cryogenetics managing director, Eli Sætersmoen.
The plan is to increase investment in the farming of salmon, halibut, trout, wolffish and cod, both in Norway and internationally.